Table 4.
Trend in ALC
| Patient | Duration of Response, mo | Baseline ALCa | ALC at 3 moa | End ALCa |
|---|---|---|---|---|
| With DCB | ||||
| VA004 | 20.5 | 1.12 | 1.61 | 1.41 |
| VA013 | 17.4 | 1.48 | 1.26 | 1.24 |
| VA007 | 17.4 | 0.96 | 1.11 | 1.26 |
| VA012 | 16.1 | 1.17 | 1.11 | 1.57 |
| VA002 | 13.4 | 1.24 | 1.25 | 1.61 |
| VA003b | 10.3 | 0.87 | 0.81 | 0.74 |
| VA001b | 9.6 | 1.14 | 1.43 | 1.62 |
| VA006 | 9.3 | 0.98 | 1.68 | 1.36 |
| VA015b | 7.7 | 1.17 | 1.82 | 1.34 |
| VA009b | 6.5 | 1.43 | 1.27 | 1.2 |
| Without DCB | ||||
| VA020 | 3.5 | 1.99 | 1.82 | 1.51 |
| VA010 | 2.5 | 1.92 | 1.02 | 1.66 |
| VA022 | 2.5 | 2.41 | NA | 1.98 |
| VA005c | 1.6 | 1.51 | NA | 1.33 |
| VA025 | 1.3 | 0.86 | NA | 0.45 |
| VA019 | 1.2 | 1.12 | NA | 1.09 |
| VA008 | 4.2 | 1.42 | 2.22 | 2.06 |
| VA017 | 5.6 | 1.35 | 1.66 | 1.65 |
| VA014c | 0.07 | 1.5 | NA | NA |
| VA018c | 3.4 | 0.78 | NA | NA |
VA005 received 2 doses of pembrolizumab but did not return for follow-up. VA014 died 2 days after receiving the initial dose of pembrolizumab. VA018 developed worsening performance status after the initial dose of pembrolizumab and elected to enroll onto hospice.
Abbreviations: ALC = absolute lymphocyte count; DCB = durable clinical benefit.
a
Reported in thousands per microliter.
b
Patient with progression of disease but continued receiving pembrolizumab after focal radiation and who showed DCB at 6 months.
c
Patients lost to follow-up after receiving ≤ 2 doses of pembrolizumab.